Neurocrine Biosciences Details $2.9B Deal to Strengthen Pipeline
- Apr 8
- 1 min read
San Diego, CA, April 7, 2026 (Yahoo Finance) -- Neurocrine Biosciences has outlined a transaction valued at approximately $2.9 billion aimed at expanding its therapeutic portfolio. The deal is designed to enhance the company’s pipeline with additional clinical-stage assets. The move supports Neurocrine’s strategy to drive long-term growth through targeted business development initiatives.
Read full article here.






















Comments